Compugen Ltd.

Compugen Ltd. logo

Compugen Ltd. is a biotechnology company that specializes in the development of therapeutic and diagnostic products. The company is headquartered in Holon, Israel, and operates in the field of computational biology and bioinformatics. Compugen is known for its innovative approach to drug discovery, utilizing advanced computational models to identify novel drug targets and biomarkers.

History

Compugen was founded in 1993 by Dr. Eli Mintz and Dr. Simchon Faigler. The company initially focused on developing computational tools for genomics and proteomics. Over the years, Compugen expanded its capabilities to include the discovery of therapeutic proteins and monoclonal antibodies.

In the early 2000s, Compugen shifted its focus towards the discovery of novel drug targets, leveraging its proprietary computational platforms. This strategic shift allowed the company to establish collaborations with major pharmaceutical companies and expand its pipeline of therapeutic candidates.

Technology

Compugen's core technology is based on its proprietary computational platforms, which integrate vast amounts of biological data to predict and validate new drug targets. These platforms include:

• Predictive Discovery Platforms: These platforms utilize algorithms to analyze genomic and proteomic data, identifying potential drug targets and biomarkers.
• Monoclonal Antibody Discovery: Compugen employs computational methods to design and optimize monoclonal antibodies for therapeutic use.
• Therapeutic Protein Discovery: The company uses its platforms to discover and develop novel therapeutic proteins with potential applications in various diseases.

Pipeline

Compugen's pipeline includes several promising candidates in various stages of development. The company's focus areas include oncology, immuno-oncology, and autoimmune diseases. Some of the key candidates in Compugen's pipeline are:

• COM701: A first-in-class immune checkpoint inhibitor targeting PVRIG, currently in clinical trials for the treatment of solid tumors.
• COM902: A monoclonal antibody targeting TIGIT, being developed for use in combination with COM701 to enhance anti-tumor immune responses.

Collaborations

Compugen has established strategic collaborations with several leading pharmaceutical companies to advance its drug discovery efforts. These collaborations provide Compugen with access to additional resources and expertise, facilitating the development of its therapeutic candidates.

Related pages

• Biotechnology
• Computational biology
• Drug discovery
• Monoclonal antibody
• Immuno-oncology